Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Podcast

FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More

Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; Novo Nordisk presents mixed results from oral semaglutide in cardiovascular disease; the EU’s Committee for Medicinal Products for Human Use declines to recommend Eli Lilly’s Alzheimer’s drug; and pharma R&D returns grew in 2024.

April 2, 2025

1 min read

Heather McKenzie

Radiopharmaceuticals

5 Big Pharmas Push Boundaries in Radiopharmaceuticals

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.

March 31, 2025

9 min read

Tristan Manalac

Aerial view of Indianapolis, Indiana skyline

Job Trends

7 Companies Hiring in Indiana

Looking for a biopharma job in Indiana? Check out the BioSpace list of seven companies hiring life sciences professionals like you.

March 27, 2025

1 min read

Angela Gabriel

Podcast

Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.

March 26, 2025

1 min read

Heather McKenzie

A look into the future. Concept. stock photo

GLP-1

BioSpace Presents the World Atlas of GLP-1s

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the territory covered and what’s to come.

March 26, 2025

2 min read

Annalee Armstrong

Contemporary art collage. Person climbs a pile of colorful capsules, symbolizing struggle and progress in surreal pharmaceutical world. Flag marks goal at top. stock photo

Manufacturing

GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.

March 26, 2025

6 min read

Ben Hargreaves

Background of scattered on a plain blue background of many tablets in the form of a silhouette of the continents of the world 3d illustration

Manufacturing

J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.

March 21, 2025

2 min read

Annalee Armstrong

Illustration silhouette people walking toward the destination of light with white line on yellow and blue empty background.

GLP-1

GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences suggest history may not repeat itself.

March 19, 2025

8 min read

Ben Hargreaves

Podcasts

COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, Viking secures ample supply of its investigational obesity medication, J&J strikes out in depression, and Makary and Bhattacharya near confirmation.

March 12, 2025

1 min read

Heather McKenzie

JOBS